The Home Depot, Inc.
$354.90B- Market cap
- $304.98B
- Debt
- +$51.31B
- Cash
- −$1.39B
Capital structure 86% equity / 14% debt · EV / Revenue 2.16x · EV proxy / EBITDA proxy 14.54x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · Mkt capMarket cap $304.98B · View financials
Snapshot Sep 10, 2026, 4:00 PM ET
Decision snapshot: HD stock price vs AVTX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AVTX's multiple
Needs AVTX P/E.
Implied fair value · at HD's multiple
Needs Annual EPS is negative.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
12 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 86% equity / 14% debt · EV / Revenue 2.16x · EV proxy / EBITDA proxy 14.54x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
The Home Depot, Inc. · implied price per share
Bear
$103.62
Base
$131.79
Bull
$172.10
AVALO THERAPEUTICS, INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LOWES COMPANIES INC
HD vs LOW
FASTENAL CO
HD vs FAST
W.W. GRAINGER, INC.
HD vs GWW
STANLEY BLACK & DECKER, INC.
HD vs SWK
WHIRLPOOL CORP /DE/
HD vs WHR
TRACTOR SUPPLY CO /DE/
HD vs TSCO
CytomX Therapeutics, Inc.
HD vs CTMX
IDEAYA Biosciences, Inc.
HD vs IDYA
Ocugen, Inc.
HD vs OCGN
CLOVER HEALTH INVESTMENTS, CORP. /DE
HD vs CLOV
Citius Pharmaceuticals, Inc.
HD vs CTXR
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe HD can continue compounding earnings and maintain its historical band rather than converging toward the DCF range, then hold or only add on pullbacks because the current price already sits near the top of the historical band and far above the DCF range.
The valuation gap is extreme: HD trades at $340.02 versus an implied price of $2,683,998.00 based on AVTX P/S approach, implying 789,264.7% downside rather than upside. That gap is driven by AVTX's tiny revenue base of $59,000 and massive negative earnings, which make a straight multiple comparison highly distorted.
Supporting Metrics